202859-52-7

Upstream product

• 202859-29-8 N-(1-benzylpiperidin-4-yl)-N-(3,4-difluorophenyl)propionamide 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 131587-53-6 1-benzyl-N-(3,4-difluorophenyl)piperidin-4-amine 
• 3863-11-4 3,4-difluoroaniline 
• 1161413-10-0 4-[(3,4-difluoro-phenyl)-propionyl-amino]-piperidine-1-carboxylic acid benzyl ester 
• 19099-93-5 benzyl 4-oxo-1-piperidinecarboxylate 
• 1161413-03-1 4-(3,4-difluoro-phenylamino)-piperidine-1-carboxylic acid benzyl ester 

Downstream Products

• 1161704-77-3 N-(3,4-difluorophenyl)-N-{1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}propionamide hydrochloride 

Relevant academic research and scientific papers

Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands

A new series of novel opioid ligands have been designed and synthesized based on the 4-anilidopiperidine scaffold containing a 5-substituted tetrahydronaphthalen-2yl)methyl group with different N-phenyl-N-(piperidin-4-yl)propionamide derivatives to study

N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS

This invention relates to /\/-aryl-/\/-piperidin-4-yl-propionannide derivatives for use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds, and to novel compounds.

N-ARYL-N-PIPERIDIN-4-YL-PROPIONAMIDE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS

This invention relates to novel N-aryl -N-piperidin-4 -yl -propionamide derivatives (I) useful as opioid receptor ligands. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds of the invention.

Pharmacological profile of a novel series of NK1, antagonists. In vitro and in vivo potency of benzimidazolone derivatives

By low throughput examination of our chemical library, compound 7 was selected as a lead NK1, antagonist with a K(i) of 7.1 nM. Modifications of its structure led to the finding that the in vitro potency could be markedly enhanced by disubstituting the anilino phenyl ring as in compounds 13 or 22. Human binding data correlated rather well with results obtained with in vitro animal smooth muscle preparations. Several agents proved to possess antinociceptive properties as exemplified in the hot-plate test in mice; compound 13 was the most active with ED50 of 0.001 and 0.3 mg/kg after iv and po administration respectively. Furthermore, antagonist 71 was found to be a potent inhibitor of SP-induced bronchoconstriction in guinea-pigs with an ED50 between 0.1 and 0.03 mg/kg iv. Furthermore, upon oral administration, 71 was observed to be active in a model of SP-induced bronchial hypersensitivity in mice, with an ID50 of around 3 mg/kg.